Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CHKA | P35790 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546310 | 0.85 | ALDH1A1 (0.53) | POLB | |
| SCHEMBL10502107 | 0.84 | SIGMAR1 (0.72) | SIGMAR1SMN1; SMN2CHKAPTGIR | |
| SCHEMBL2722352 | 0.81 | CCR3 (0.64) | SIGMAR1 | |
| SCHEMBL5542406 | 0.81 | SIGMAR1 (0.56) | SIGMAR1SMN1; SMN2CHKAPOLBPKM | |
| SCHEMBL11465645 | 0.80 | SIGMAR1 (0.66) | SIGMAR1SMN1; SMN2CHKA | |
| SCHEMBL1043952 | 0.79 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2CHKAPOLBPKM | |
| SCHEMBL20804352 | 0.79 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2CHKAPOLBPKM | |
| SCHEMBL19285228 | 0.79 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2CHKAPOLBPKM | |
| SCHEMBL11158126 | 0.79 | SIGMAR1 (0.64) | SIGMAR1SMN1; SMN2CHKA | |
| SCHEMBL15586023 | 0.77 | SIGMAR1 (0.62) | SIGMAR1SMN1; SMN2CHKAPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SIGMAR1 234/4885SMN1; SMN2 3985/4885CHKA 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.